Roneet Lev, MD, FACEP
Executive Director, IEPC

CS-1103 is entering Phase 2 trial. The new drug is a sequestrant that bind methamphetamine within minutes. California is ground zero for meth and we see methamphetamine toxicity daily in the form of agitation, mental health crisis, and cardiac effects. You can read more about CS1103 in an article on Kevin MD.